MicroPort Scientific (HKG:0853) expects to record a net loss of about $275 million for 2024, a decrease of 58% compared with the same period a year earlier, according to a Friday filing with the Hong Kong bourse.
The company attributed the narrowing of loss to the 10% revenue growth despite industry challenges, with overseas business increasing 80% year-on-year. Cost optimization improved efficiency, reducing the operating expense ratio by 28% points year-on-year. Additionally, the successful divestment of non-core businesses contributed positively to the overall financial performance.
The manufacturer and sellers of medical products plan to publish their annual results by the end of March.
The company's shares were down over 5% at the close of trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。